AU Patent

AU2018275545B2 — Rapid-acting insulin compositions

Assigned to Eli Lilly and Co · Expires 2021-02-04 · 5y expired

What this patent protects

The invention is a composition of insulin or insulin analog that has faster pharmacokinetic action than commercial formulations of rapid-onset insulin analog products.

USPTO Abstract

The invention is a composition of insulin or insulin analog that has faster pharmacokinetic action than commercial formulations of rapid-onset insulin analog products.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018275545B2
Jurisdiction
AU
Classification
—
Expires
2021-02-04
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.